Overview
Verana Health and Guardant Health have partnered to combine curated real-world clinical data with longitudinal clinicogenomic testing data.
The collaboration aims to help biopharmaceutical researchers better connect molecular biomarkers, treatment decisions, and patient outcomes to support precision oncology and accelerate drug development.
The News
Verana Health has partnered with Guardant Health to provide biopharmaceutical researchers with access to combined real-world clinical and clinicogenomic datasets. Verana’s regulatory-grade, therapeutic-specific EHR data from academic and community medical centres will be integrated with Guardant’s longitudinal genomic testing data spanning tumour profiling, treatment selection, recurrence, and therapy response monitoring.
The combined data could help researchers refine risk assessment, improve treatment selection, and validate biomarkers using real-world outcomes. In non-muscle-invasive bladder cancer, for example, the datasets could help identify which patients may benefit from BCG therapy and which may require earlier treatment escalation. The collaboration will also expand Verana’s oncology data capabilities across solid tumours, including lung, breast, and colorectal cancers.
Industry Perspective
Linking genomic information with longitudinal clinical outcomes can help researchers better understand treatment response and develop more targeted therapies. The growing use of real-world and clinicogenomic data is also supporting more efficient drug development and biomarker validation.
Strategic Impact
The partnership strengthens Verana Health’s precision oncology capabilities and expands the breadth of data available to life sciences companies. Following Verana’s merger with COTA, the combined company serves 17 of the top 20 global biopharma companies and provides access to more than 95 million patients and over 20,000 contributing clinicians, including more than 30 academic medical centres. Its oncology network now includes access to more than 10 million patients, supporting clinical research, regulatory submissions, health economics, and market-access strategies.
Source: PRnewswire
